Introduction
The ability of estrogen, a well-defined female hormone, to act as a feedback regulator of gonadotropins in both the female and male mammal is well known. The physiological role of estrogen in regulating testicular function, however, appears ill understood, and this perhaps is due to relatively low amounts of estrogen produced by the male as compared to the female. Although earlier studies led to the assertion that estrogen is synthesized by Leydig cells in adults and by Sertoli cells in prepubertal males [1] [2] [3] [4] [5] [6] there are also reports indicating that the seminiferous epithelium of the adult animal is capable of estrogen synthesis. 7 Germ cells 8 as well as placental tissue 9 are also known to exhibit P-450 aromatase activity. Some of the recent studies involving the blockade of estrogen action by follicle regulatory proteins in male rats and dogs 10 -12 and insertional disruption of estrogen receptor genes in rodents 13, 14 have indicated that estrogen may be required for normal testicular function in the male. In addition, the presence of estrogen receptors in the epididymis [15] [16] [17] suggests a positive role for estrogen in sperm maturation.
Blockade of estrogen synthesis by specific aromatase inhibitors (AIs) is one of the best ways of studying estrogen action in vivo. Treatment with AI has been shown to enhance luteinizing hormone (LH) and testosterone (T) secretion in the human male 18, 19 and cynomolgus monkeys, 20 a positive feedback effect of estrogen deprival. In the present study, in bonnet monkeys (M. radiata) a new generation nonsteroidal aromatase inhibitor of high specific activity, CGP 47645 [a fluoridated analog of Letrozole (CGS 20267), a much more widely studied AI] has been used to investigate the effect of blocking estrogen synthesis on testicular testosterone as well as sperm production. The results of our study, we believe, provide a better understanding of the physiological role of estrogen in regulating fertility in the male primate.
Experimental

Hormones and chemicals
The ovine luteinizing hormone (oLH) used was a laboratory preparation, with 1 ng of this material exhibiting an activity profile equivalent to 0.133 ng NIH-hLH (AFP-4745B) in the radio receptor assay. Tritiated T (97 ci/m mol) was purchased from Amersham, UK. Aromatase inhibitor CGP47645 was donated by CIBA Geigy Ltd, Basel, Switzerland. Dithiotreitol (DTT), ethidium bromide (EB), RNase, and Nonidet P-40 were from Sigma, St Louis, MO, USA. Papain and Dulbecco's phosphate buffered saline (DPBS) were obtained from Himedia, Bombay, India.
General methodology
Five healthy adult male bonnet monkeys ages 8 -12 years weighing 7-9 kg each screened for normal diurnal T rhythms and spermatogenesis (by DNA flow cytometry using testicular tissue obtained by needle biopsy as well as semenology) were used for the study. The general care and maintenance of monkeys under conditions of controlled photo period (12L:12D) has been described earlier. 21 The present study was cleared by institutional ethical committee for use of non-human primates for biomedical research.
Treatment
A dose of 2.5 mg of CGP 47645 dissolved in 2.5 mL of ethanol was given by oral route (by means of a dropper) once every 5 days. This dose of AI was arrived at by determining the estrogen synthesis inhibiting efficacy as well as the duration of the effect of a single dose of the drug in appropriate rat and female monkey test systems. 22, 23 Oral administration of 50 g of CGP 47645 to immature rats totally blocked the PMSG-induced increase in the uterine weight for a minimum of 6 days. A single oral administration of CGP 47645 (2.5 mg) to female monkeys on Day 7 of the cycle prevented estrogen levels increasing from a basal of Ͻ80 pg/mL for the following 6 days. Normally, estrogen levels between Days 8 -9 of the cycle range between 200 -600 pg/mL. In addition, the administration of a single oral dose of CGP 47645 (4 mg/ monkey) to adult male monkeys resulted in serum testosterone being elevated over the control values for the succeeding 12 days; maximal increment, however, was achieved by the sixth day of administration. 23 On the basis of these observations and considering that the production of estrogen in the male compared to the female is low, it was assumed that oral administration of 2.5 mg of CGP 47645 to adult males should be adequate to block the aromatase activity for a minimum of 5 days.
Blood sampling and testosterone assay
Blood samples were collected from unanesthetized monkeys by way of femoral vein/arterial puncture using sterile vacutainer tubes (Becton-Dickinson, New Jersey, USA) at 10.00 and 20.00 h of the day and represented a.m. and p.m. values. The sera was separated within 12 h and stored at Ϫ20°C until analysis.
Testosterone was analyzed by a specific radioimmunoassay described in detail earlier 24 using ether extracted serum samples. The sensitivity of the assay was 10 pg/tube, and the inter and intra-assay coefficients of variation were 9.8% and 8.3%, respectively. The aliquot of serum sample used for assay varied depending upon whether T was being measured in a.m. or p.m. samples of control and AI-treated monkeys.
Quantitation of testicular germ cells by DNA flow cytometry
Testicular needle biopsy was performed under ketamine anaesthesia as described earlier. 25 Preparation of single-cell suspension of testicular germ cells 26, 27 and the procedure adapted for pepsinization and DNA staining of ethanol fixed cells with ethidium bromide have been described earlier. 27, 28 The flow cytometric analysis of stained germ cells was carried out using a FACScan (BectonDickinson, San Jones, CA, USA) flow cytometer equipped with an argon ion laser. At least 10,000 cells per sample were acquired and analysed using the LYSIS II software program (BectonDickinson). The germ cell distribution pattern (using leukocytes as internal diploid marker) showed four distinct cell populations based on DNA content-spermatogonia (2C), the cells in synthetic phase and primary spermatocytes (4C), round spermatids (1C), and elongating/elongated spermatids (HC). It was, however, possible to apply electronic gating to differentiate between elongating (HC1) and elongated (HC2) spermatids. The germ cell transformation ratios were calculated from % cell populations.
Ejaculated sperm samples from treated and control animals were decondensed by treating with DTT, the chromatin exposed to ethidium bromide and flow cytometrically analysed as described earlier. 29 The DTT treatment brought about reduction of free thiol groups in the protamine.
Seminal parameters
Semen samples collected at 10-to 15-day intervals by electroejaculation were analyzed for sperm count and motility according to the procedure described in the WHO manual 1992. 30 
Statistical analysis
All data are expressed as mean Ϯ SEM. Significance of differences between T levels, testicular germ cell percentages, and seminal parameters during pretreatment and treatment phase were analyzed by Student's t test.
Results
Effect of CGP 47645 on serum T profile of adult male monkeys
Oral administration of CGP 47645 at a dose of 2.5 mg once in 5 days over a period of 85 days resulted in a significant and sustained increment (approximately 10-fold increase in the basal and 5-fold increase in nocturnal values) in serum T levels. However, the high levels of serum T could not be maintained beyond 85 days of treatment, the nocturnal high levels reaching normal values by Day 180 of continued treatment. The basal levels of T all the same continued to be significantly high ( p Ͻ 0.05) for the entire period of 180 days ( Figure 1 ).
Effects of AI treatment on seminal parameters
Sperm count of four out of five treated monkeys was markedly reduced between Days 55-85 of treatment. At time points beyond this, the reduction in the sperm count of individual animals was not significant at consecutive time points, although the average counts did not revert back to (Figure 2b ). The variation in sperm counts of a group of control monkeys analysed over the same time period was within 10% of Day 0 value.
Effect of blocking estrogen synthesis on spermatogenesis
DNA flow cytometric analysis of germ cells processed from testicular biopsy tissue taken on Day 0, 63, and 120 of treatment showed that there was no significant change in the relative population of spermatogonia (2C), primary spermatocytes (4C), and cells in synthetic phase (S-ph; Table 1 ). However, from the composite flowcytogram of the spermatid population obtained, it was evident that estrogen deprivation effected spermiogenesis (Figure 3) . The transformation of round to elongating spermatids (HC1:1C) was inhibited by 47 and 53% by Days 63 and 120 of treatment, respectively. The elongated spermatid population (HC2) was reduced at Days 63 and 120 by 43 and 81%, respectively ( p Ͻ 0.001), and the transformation of round to elongated spermatid (HC2:1C) population at the above two time points appeared reduced by 15 and 88%, respectively. The overall HC1 ϩ HC2:1C ratio changed from a normal of 1.11 (pretreatment value) to 0.78 by Days 63 and to 0.32 by Day 120 of treatment (Table 1) , suggesting thereby that the lack of estrogen affects spermiogenesis specifically (transformation of round to elongating and elongated spermatids).
In vivo response of AI-treated monkeys to oLH
To better understand the functionality of Leydig cells in the AI-treated animals, the acute in vivo response of these monkeys to a bolus i.v. injection of oLH (1 mg) was determined. The results showed that the responsivity of the AI-treated monkeys (n ϭ 2) as compared to the controls (n ϭ 2) was twofold higher in terms of serum T production ( Figure 4) .
Susceptibility of ejaculated sperms of control and AI-treated monkeys to DDT-induced decondensation
Flow cytometric analysis showed that whereas sperm chromatin of control monkeys exhibit maximal decondensation when exposed to DTT concentrations of 5 mM and higher, sperm of AI-treated monkeys showed significant reduction ( p Ͻ 0.002) in decondensability even at 20 mM DTT ( Figure 5 ).
Discussion
It is well recognized that in the primate as in other mammals testicular testosterone production is under LH control. 24 Testosterone has long been held as the primary feedback regulator of LH in mammals. AI is expected to block estrogen synthesis not only in major steroidproducing organs like the testis and adrenal but also in other tissues, such as the hypothalamo-pituitary-axis placenta. Its use in the current study clearly establishes that it is estrogen rather than T that acts as the primary feedback regulator of gonadotropins (and as such T production) in the male primate. This is in agreement with earlier studies in primates (References 18 -20 and 31-33). In rodents aromatization also is known to be essential for androgen-regulated feedback control of gonadotropins. 34 Deprivation of estrogen by using a nonsteroidal AI (CGS 16949A), however, results in an increase in LH level in the female 35 but not in the male rat (Reference 18, Shetty et al., unpublished data). The above observations also correlate with the recent observations in male mice 14 in which estrogen action was compromised by targeted disruption of estrogen receptor gene. The repeat administration of the drug as carried out in the current monkey study could, by continuously inhibiting aromatase activity at the hypothalamo-pituitary axis, result in an increase in endogenous-circulating LH levels leading to a significant increase in serum T. The inability of the drug to maintain nocturnal serum T levels at supraphysiological levels beyond Day 90, however, seems currently unexplainable. In an attempt to determine whether this is due to Leydig cells becoming desensitized to continuous stimulation by endogenous LH (perhaps as a consequence of lifting of feed back inhibition), monkeys were challenged on Day 166 of drug treatment with a bolus injection of oLH. The results showed that there was a good response to the bolus, in fact a response better than that provided by controls. This experiment all the same does not overrule completely the setting in of desensitization as we have observed earlier that the monkey testis could be desensitized to the action of a relatively lower level of endogenous LH administered several hours before a bolus injection of LH. These monkeys, although exhibiting a blockade of naturally occurring nocturnal testosterone surges, do respond to a bolus injection of LH by producing high T levels. 36 Alternately it is possible that following continuous exposure to the drug the monkeys have developed newer metabolic clearance pathways for the drug resulting in its rapid clearance. The AI used here, CGP 47645, is known to have a relatively longer half-life than CGS 20267 and CGS 16949A. 23 Treatment of dogs with the AIs CGP3249 and CGS 20267 has been suggested to cause hypertrophy and hyperplasia of testicular Leydig cells. 37 Furthermore, estrogen produced by germ cells has been suggested to have a regulatory influence on androgen production through a negative feedback affect on Leydig cells. 8 The current study has shown that the blockage of estrogen synthesis leads to compromise only in spermiogenesis and not spermatocytogenesis. Besides, the functional ability of sperm produced during Day 40 -120 of treatment also seemed impaired. The flow cytometric analysis of germ cells indicated significant reduction in elongating/elongated population of spermatids between Days 60 to 120 of treatment, and this may be the reason for observing a marked reduction in sperm count during the early period of drug treatment. An additional parameter of defective spermiogenesis and sperm maturation was the observation that sperm motility was markedly reduced (a score of 0-2) in the treatment group compared to a score of 3-5 in the control group of monkeys, and this led to significant lowering of calculated fertility index (a product of motility score and sperm counts). Monkeys exhibiting fertility index below 500 have been observed by us earlier to be infertile. 38 The reduction in motility and concentration of sperms caused due to lack of estrogen may be due to more than one reason. Estrogen receptors are known to be present in sertoli cells 39 as well as epididymis. 17 In addition, the presence of P450 aromatase in germ cells (relatively more in spermatid than pachytene spermatocytes) of rodents has been reported. 8 It has been hypothesized that estrogen produced by the germ cells may have a role in gene expression of spermatogenic or epithelial cell function in epididymis. 8, 14 This suggests that changes in sperm motility and concentration in AI-treated monkeys may be caused by the loss of estrogen action in Sertoli as well as germ cells. Improper or poor maturation of sperm during epididymal transit due to estrogen lack could be the cause of observed hypercondensation of sperms of AI-treated monkeys. This was of particular interest to us as we recently reported that vulnerability to DTT-induced decondensation of monkey sperms markedly increases following specific follicle-stimulating hormone deprivation. 40, 41 Interestingly, both hyper-and hypocondensation of ejaculated sperms have been correlated with infertility. 42 In rodents, the blockage of estrogen action either by using aromatase inhibitors 13, 14 or by the disruption of estrogen receptors 13, 14 has been shown to impair fertility in general. Evidence indicating impairment in testicular function such as atrophy of interstitial cells, 37 disruption of seminiferous epithelial function, 11, 14 reduced sperm function, 14 and sexual activity 14, 43, 44 following the blockage of estrogen function has also been reported. In conclusion, by observing that a specific lack of estrogen lack in adult male monkeys leads to defective spermiogenesis, which is accompanied by marked reduction in the quality and quantum of sperm produced, we tend to believe that estrogen could play a crucial role in regulating fertility in the male primate.
